Lung Cancer Clinical Trial
Official title:
Gene-expression Profile as Predictor of Central Nervous System Metastasis Development in Non-small Cell Lung Cancer: a Prospective Study
Non small-cell lung cancer (NSCLC) accounts 85% of all lung cancer.The development of brain metastasis diminished life expectancy to less than one year with a median survival of less than three months. In NSCLC cancer, approximately 50% of patients with locally advanced disease develop brain metastasis at some time during the natural of disease. The central nervous system constitutes the first site of recurrence in 15 to 40% of these patients. Microarrays evaluate the diagnosis, treatment and prognosis of lung cancer.There are no studies that specifically evaluate the relationship between a genetic profile of NSCLC and metastasis to the CNS, with the purpose of distinguishing a subgroup of patients that will benefit of prophylactic treatment.What is the association between a genetic profile on NSCLC and the development of CNS metastasis.Obtaining a genetic profile from the primary NSCLC tumor cells, by using microarrays, we can predict the development of CNS metastasis arise a subgroup of patients that could benefit from prophylactic cranial radiation with which their quality of life and prognosis most probably will increase.Objective:Determine the association between a genetic profile from the primary tumor cells and the development of central nervous system metastasis in patients with non small-cell lung cancer.A genetic profile from the primary tumor cells are associated with the development of central nervous system metastasis in patients with NSCLC. A clinical, prospective, analytic, open, non randomized, prognostic and observational cohort with 66 patients with NSCLC who authorize a biopsy study from February, 2008 to December, 2012, INMEGEN institute will be in charge of performing the microarrays and the computer analysis in order to obtain the different genetic profiles that will be differentially expressed related with CNS metastasis risk profiles. Patients will be followed-up by means of the external consult of lung neoplasms. The statistical analysis will be performed using tests like Student's t or Mann-Whitney's U test. A multivariate analysis of logistic regression will be performed. Global survival time will be analyzed using Kaplan-Meier's technique and the comparison between groups will be performed with log-rank test. The adjustment for potential confusors will be performed using multivariate regression analysis. For result representation, we will use tables and graphs and pertinent measures will be taken to disclose the study.
Brain metastases occur in 30-50% of lung adenocarcinoma (LAC) patients and confer a worse
prognosis and quality of life. A better selection of in-risk patients through a more
accurate biomarker could improve the benefit of prophylactic therapies. The aim of this
prospective study was to determine a gene-expression profile of primary tumor associated
with brain metastasis (BM) and to evaluate the overall survival (OS) in patients with
advanced LAC.
Introduction.Lung cancer is the first cause of cancer death in the world. Eighty five
percent of patients are diagnosed yearly with non-small cell lung cancer (NSCLC). Despite
efforts, innovations, and progress in diagnosis and treatment of these patients, overall
survival (OS) at 5 years of diagnosis is only 15%. The central nervous system (CNS) is a
devastating and frequent site of metastasis development in NSCLC. The reported incidence of
CNS metastasis in patients with NSCLC is 54% with an OS of <1 year after diagnosis. Age,
clinical stage, gender, and initial treatment period are some of the reported with CNS
metastasis development-related factors in patients with NSCLC. We recently described that
high carcino-embryonic antigen (CEA) serum levels (>40 ng/dL) at diagnosis and
adenocarcinoma histological type are independently associated with higher risk if brain
metastasis development. However, due to their lack of specificity of all this reported
factors, we are required to detect biomarkers to predict brain metastasis in patients with
NSCLC with the objective to prevent their development.Metastasis process is complex it
involves well-defined molecular-printed steps, as invasion, vascular intravasation,
implantation and growing at the new specific organ. Higher motility, capacity for
extracellular matrix degradation, immune system evasion, and adhesion at the new specific
organ are some of the tumoral cell characteristics required to metastasize. In particular,
molecular events for brain metastasis development from primary NSCLC even if no at al
described, are currently well understood. Gene-expression microarray allow analyzing the
expression changes of thousands of genes simultaneously, distinguishing the altered
expression of neoplastic cell genes from normal tissue. Identification of biological
patterns, pharmacological molecular targets, and biomarkers for prognosis and evaluation for
therapeutic response, and even a more specific neoplasia classification are some of the
results of gene-expression microarray studies in hematological, breast and NSCLC cancer.
Determination of tobacco-smoke transcriptional changes in oncogenes and antioncogenes had
been determined by the use microarray data. A gene-expression profile of 20 genes
differentiates health lung tissue and lung cancer with higher specificity than
histopathologic evaluation. Furthermore, gene-expression microarray studies had been
developed for predicting survival and recurrence in early NSCLC stages for identification of
patients who could have benefit of adjuvant therapy, with promising result.The objective of
this study was to identify a gene-expression profile from primary lung adenocarcinoma
related with brain metastasis, and to evaluate in a prospective manner their prognostic
significance on survival in patients with advanced disease.Experimental Design These study
used clinical, longitudinal, prospective, observational, and analytical cohort s with the
selection of a nonprobabalistic-type sample.In a prospective manner, from January 2009 to
June 2011, patients admitted to our Institute confirmed histologically confirmed stage IIIb
and IV of LAC were eligible for study inclusion. Analyzed clinical variables comprised
smoking history, gender, age, general condition and brain metastasis development. Primary
tumor core-biopsy was performed prior to any treatment and snap-frozen. A single pathologist
evaluated all tumors. Standard platinum-based chemotherapy was employed for all patients.
All patients were submitted to Magnetic resonance imaging (RM) to evidence the presence or
absence of brain metastasis (BM). During follow-up, we carried out Computed tomography (CT)
of the brain stem for this purpose. Preliminary statistical analysis was performed utilizing
the Student t, the Mann-Whitney U, the χ2, or the Fisher exact test. Once the study ends, we
will conduct logistic-regression multivariate analysis. Global survival time will be
analyzed with the Kaplan-Meier technique, and comparisons among groups will be performed
with the log-rank test. High Risk characteristics as gender, histology, and age related with
greater frequency of development of metastasis to CNS were analyzed.The study was carried
out according to the principles of ClinicalTrials and accepted by the INCan Bioethical and
Scientific Committees (reference numbers INCAN/CC/067/08). A collaboration agreement was
signed with the INMEGEN and was approved within the Health Research Sectorial Fund (FSIS)
CONACyT-México (SALUD-2009-01-115552).
Selection for obtaining tumor biopsies depended on the characteristics of the patient and of
the tumor. The biopsy could be taken by means of CT guided tru-cut needle, open
thoracoscopy, or bronchoscopy with optic fiber. Each tumor sample was divided into two; one
sample was analyzed by the INCan Pathology Service (by a sole observer blinded to the
clinical variables) for their histological clinical diagnosis and quantification of
neoplastic cellularity, and the remaining half was immediately stored at ‒80°C until
processing for RNA extraction.RNA Extraction:RNA was extracted from frozen tumor biopsies,
weighted and cryofractured in liquid nitrogen. Extraction and purification of total RNA from
tissue (up to 5 mg tissue) procedure was done using RNeasy Micro Kit (QIAGEN, Germany) (cat.
217084). RNA was analyzed using the Agilent 6000 Chip (Agilent Technologies, Santa Clara,
C.A.). RNA quality consisted on the obtention of RNA Integrity Number (RIN) > 8. RNA samples
were chosen for microarray analysis when quality and concentration were obtained for this
purpose. Microarray Expression:We are using an Affymetrix platform, which consists of an in
situ synthesized oligonucleotide microarray. The GeneChip® that we are employing is the
Human Gene 1.0 ST Array, which allows analyzing the expression of 28,869 different genes
(each transcript is represented by 26 disperse probes along its entire length, present in
the human genome, which covers 99% of the sequences present in the RefSeq data bank of the
GenBank. The Two-Cycle Target Labeling protocol is followed as suggested by the manufacturer
and described succinctly as follows and shown graphically in the figure at the end of this
Materials and Methods section: Total RNA (100 ng/uL) is retro-transcribed using T7-Oligo(dT)
Promoter primers in the synthesis reaction of the first complementary DNA chain (cDNA).
After treatment with RNAase H, the second cDNA chain is synthesized, which will serve as
template in the Transcription reaction in vitro (TVI). The first TVI reaction is carried out
with T7 polymerase RNA and unmarked ribonucleotides for the amplification of complementary
RNA (cRNA). These cRNAs are retro-transcribed in the synthesis step of the first cDNA chain
of the second cycle using random primers. Subsequently, T7-Oligo(dT)-Promoter primers are
employed for the synthesis of the second chain of cDNA, generating the double-helix cDNA
template that contains the promoter T7 sequence. This cDNA is amplified and marked in a
second TVI reaction using the T7 polymerase DNA and a mixture of
ribonucleotides/biotinylated nucleotide analog. These target biotinylated cDNAs are cleaned,
fragmented, and hybridized to the GeneChip® expression microarrays. After hybridization,
fluorescent marking was performed with a streptavidin-phycoerythrin and biotinylated
anti-streptavidin antibody amplifier system. Fluorescence is detected with a high-resolution
laser scanner.Reading and Analysis of Expression Microarrays:We will utilize the Expression
Console of Affymetrix software to evaluate the quality of the microarrays and will correct
the background signal with standard methods [49,50]. For signal intensity-level
normalization, we will employ "non-supervised" methods, which use the data of all of the
experiment's microarrays; this will allow us to render these comparable among themselves,
because what a microarray assay evaluates is gene expression by means of fluorescence
intensities; thus, it is important to establish cut-off points from which we can consider
under- or overexpression. Once the data are normalized, the final stage is to resume the
values of all the probes that exist for each gene in the microarray in a sole value, which
is the gene's expression level. For detection of differentially expressed genes, we will
construct a linear model that includes all of the experiment's microarrays simultaneously;
in this manner, we will be able to analyze contrasts between group A (patients with
metastasis to CNS during the follow-up period) and group B (patients without metastasis to
CNS during the same period). As internal control, we will prove the differential expression
of some genes by RT-PCR in real time. Results will be represented in blocks of heat maps and
in tables, in which the most active genes are listed along with their functional
description. For risk-profile validation, we will perform leave-one-out cross validation
method and will postulate a second cohort for this objective.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|